{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"MetaVia Inc. "},"Symbol":{"label":"Symbol","value":"MTVA"},"Address":{"label":"Address","value":"200 BERKELEY STREET,OFFICE 19TH FLOOR, BOSTON, Massachusetts, 02116, United States"},"Phone":{"label":"Phone","value":"+1 857 702-9600"},"Industry":{"label":"Industry","value":"Biotechnology: Pharmaceutical Preparations"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"NeuroBo Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing and commercializing multi-modal disease-modifying therapies for viral, neuropathic, and neurodegenerative diseases, has a current portfolio of four drug candidates. The company's acquired ANA001 candidate is a proprietary oral niclosamide formulation in development as a treatment for patients with moderate to severe COVID-19. ANA001 is being studied in a 60-subject Phase 2/3 clinical trial conducted at up to 20 clinical sites in the USA. The company's NB-01 candidate has been shown in a Phase 2 study to significantly reduce pain symptoms associated with painful diabetic neuropathy (PDN), with a superior safety profile when compared to currently available treatments."},"CompanyUrl":{"label":"Company Url","value":"https://www.neurobopharma.com"},"KeyExecutives":{"label":"Key Executives","value":[]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}